339 predictions since April 2026 — each with a permalink, confidence, and public resolution status. Nothing is deleted.
| Date | Prediction | Conf. | Status |
|---|
| 2026-07-02 | Any approved psychedelic drug will require special certified clinics | 82% | ⏳ Pending |
| 2026-07-02 | Psychedelics stay illegal federally except in approved medical settings | 78% | ⏳ Pending |
| 2026-07-02 | Approved psychedelics will require supervised clinics, not free access | 76% | ⏳ Pending |
| 2026-07-02 | No law to loosen federal psychedelic restrictions will pass in 2026 | 75% | ⏳ Pending |
| 2026-07-02 | At least two small psychedelic companies will merge or get bought out by early 2027 | 75% | ⏳ Pending |
| 2026-07-01 | Psilocybin stays on the most restricted drug list for now | 78% | ⏳ Pending |
| 2026-07-01 | Psilocybin stays on the most restricted drug list for now | 75% | ⏳ Pending |
| 2026-07-01 | The FDA won't approve a psilocybin drug within 18 months | 75% | ⏳ Pending |
| 2026-07-01 | MDMA's FDA decision will swing the whole psychedelic market 25% either way | 72% | ⏳ Pending |
| 2026-07-01 | Brain scan findings hold up, but specific disease cure claims need fixing | 72% | ⏳ Pending |
| 2026-06-30 | No psychedelic drug gets full US approval in 2026 | 76% | ⏳ Pending |
| 2026-06-30 | Magic mushrooms and LSD stay fully illegal federally through 2026 | 72% | ⏳ Pending |
| 2026-06-30 | Psychedelic company stocks mostly stay flat through mid-2026 | 71% | ⏳ Pending |
| 2026-06-30 | Strong trial results for psilocybin treating addiction published by mid-2027 | 68% | ⏳ Pending |
| 2026-06-29 | Psilocybin and MDMA stay illegal federally through 2026 | 78% | ⏳ Pending |
| 2026-06-29 | No federal legalization change for psychedelics in 2026 | 77% | ⏳ Pending |
| 2026-06-29 | Congress won't legalize psilocybin in 2026, but may fund veteran programs | 75% | ⏳ Pending |
| 2026-06-29 | FDA will not approve psilocybin in 2026; MDMA needs more proof first | 74% | ⏳ Pending |
| 2026-06-29 | Psychedelic company stock prices will stay flat through mid-2026 | 72% | ⏳ Pending |
| 2026-06-28 | A major depression drug trial posts promising results in 2026 | 80% | ⏳ Pending |
| 2026-06-28 | Any approved psychedelic drug will come with strict ongoing safety rules | 78% | ⏳ Pending |
| 2026-06-28 | Psychedelics stay in the most restricted drug category for at least another year | 75% | ⏳ Pending |
| 2026-06-28 | Depression trial results look promising but work better for some patients than others | 74% | ⏳ Pending |
| 2026-06-28 | Federal law on psychedelics will not change in the next 12 months | 74% | ⏳ Pending |
| 2026-06-27 | No psychedelic therapy will get US government approval in 2026 | 85% | ⏳ Pending |
| 2026-06-27 | The US government won't reclassify mushrooms or MDMA in 2026 | 82% | ⏳ Pending |
| 2026-06-27 | One company's mushroom drug trial results will cause a massive stock swing | 76% | ⏳ Pending |
| 2026-06-27 | The big psilocybin trial will likely show the drug actually works | 70% | ⏳ Pending |
| 2026-06-27 | Experts will publicly question whether the trial results are trustworthy | 68% | ⏳ Pending |
| 2026-06-26 | Psilocybin and MDMA stay illegal at the federal level in 2026 | 80% | ⏳ Pending |
| 2026-06-26 | Federal drug law won't change, but veterans may get easier research access | 79% | ⏳ Pending |
| 2026-06-26 | Scientists will zero in on how psychedelics reduce brain inflammation and rewire connections | 75% | ⏳ Pending |
| 2026-06-26 | No psychedelic drug will get full FDA approval in 2026, but a strict conditional path may be proposed | 70% | ⏳ Pending |
| 2026-06-26 | Psychedelic stock gains will likely reverse fast without hard clinical trial data | 66% | ⏳ Pending |
| 2026-06-25 | Ketamine drugs will get US approval before MDMA or psilocybin | 74% | ⏳ Pending |
| 2026-06-25 | Magic mushrooms will stay federally illegal for at least two more years | 72% | ⏳ Pending |
| 2026-06-25 | Congress won't legalize magic mushrooms — small veteran bills are the best case | 72% | ⏳ Pending |
| 2026-06-25 | Any approved psychedelic drug will come with very strict safety controls | 72% | ⏳ Pending |
| 2026-06-25 | Approved psychedelics will face tight government controls, not open access | 70% | ⏳ Pending |
| 2026-06-24 | The DEA won't change psilocybin or MDMA's legal status in 2026 | 78% | ⏳ Pending |
| 2026-06-24 | Congress won't pass a federal psychedelic drug reform law in 2026 | 76% | ⏳ Pending |
| 2026-06-24 | If MDMA gets approved for PTSD treatment, it will come with strict conditions attached | 74% | ⏳ Pending |
| 2026-06-24 | Psilocybin won't get FDA approval as a medicine in 2026 | 73% | ⏳ Pending |
| 2026-06-24 | Scientists will publicly push back on overhyped psychedelic treatment claims | 70% | ⏳ Pending |
| 2026-06-23 | MDMA stays illegal federally even if the FDA approves it | 78% | ⏳ Pending |
| 2026-06-23 | MDMA stays in the most restricted drug category through 2026 | 76% | ⏳ Pending |
| 2026-06-23 | No federal law legalizing psychedelics in 2026 — states lead the way | 75% | ⏳ Pending |
| 2026-06-23 | FDA will attach strict conditions to any MDMA approval — not a free pass | 74% | ⏳ Pending |
| 2026-06-23 | Any MDMA approval comes with tight restrictions and required follow-up studies | 72% | ⏳ Pending |
| 2026-06-22 | Psilocybin and MDMA stay on the US banned list through 2025 | 85% | ⏳ Pending |
| 2026-06-22 | US Congress will not pass a law legalizing these drugs by 2025 | 80% | ⏳ Pending |
| 2026-06-22 | A key flaw in psychedelic drug trials will keep making headlines | 80% | ⏳ Pending |
| 2026-06-22 | MDMA therapy for trauma will not get US approval by end of 2025 | 78% | ⏳ Pending |
| 2026-06-22 | Any approved psychedelic therapy must happen in a monitored clinic | 74% | ⏳ Pending |
| 2026-06-21 | No psychedelic drug will get US approval in 2026 | 74% | ⏳ Pending |
| 2026-06-21 | Psychedelics will stay in the most restricted drug category through 2026 | 74% | ⏳ Pending |
| 2026-06-21 | Congress will only fund small veteran-focused psychedelic pilot programs | 70% | ⏳ Pending |
| 2026-06-21 | No psychedelic treatment approved using only real-world patient data by mid-2027 | 69% | ⏳ Pending |
| 2026-06-21 | DEA will crack down on at-home ketamine prescribed over video call | 68% | ⏳ Pending |
| 2026-06-20 | The DEA will not change psilocybin or MDMA's illegal status this year | 72% | ⏳ Pending |
| 2026-06-20 | Congress will not vote on rescheduling psychedelics within 12 months | 71% | ⏳ Pending |
| 2026-06-20 | The FDA will add major conditions before approving MDMA as a medicine | 70% | ⏳ Pending |
| 2026-06-20 | A psychedelic company's stock will jump or crash more than 20% in a single day | 70% | ⏳ Pending |
| 2026-06-20 | Science is advancing faster than clinics can safely standardize psychedelic treatments | 68% | ⏳ Pending |
| 2026-06-19 | Drug approval rules and scheduling delays will limit who gets access | 74% | ⏳ Pending |
| 2026-06-19 | A psychedelic drug could get approved and reach patients faster than expected | 74% | ⏳ Pending |
| 2026-06-19 | The DEA's separate drug reclassification will delay real patient access by at least six months | 74% | ⏳ Pending |
| 2026-06-19 | A psychedelic medicine will likely get FDA approval within the next year | 72% | ⏳ Pending |
| 2026-06-19 | FDA approval of a psychedelic could spark real political action in Congress | 72% | ⏳ Pending |
| 2026-06-18 | Approved psychedelic drugs will only be available at licensed, supervised clinics | 82% | ⏳ Pending |
| 2026-06-18 | Magic mushrooms will stay federally illegal all year, no matter what | 80% | ⏳ Pending |
| 2026-06-18 | Psilocybin remains federally illegal this year; federal approval and scheduling are separate slow processes | 79% | ⏳ Pending |
| 2026-06-18 | DEA won't change psilocybin's legal status even if the FDA approves it for medicine | 78% | ⏳ Pending |
| 2026-06-18 | If approved, psychedelic treatments will only reach a small fraction of patients at first | 75% | ⏳ Pending |
| 2026-06-17 | Psychedelics stay illegal at the federal level through 2026 | 85% | ⏳ Pending |
| 2026-06-17 | Congress won't pass a broad psychedelics law in 2026 | 82% | ⏳ Pending |
| 2026-06-17 | No psychedelic drug gets FDA approval in 2026 | 80% | ⏳ Pending |
| 2026-06-17 | A psychedelic stock's big one-day spike likely fades fast | 70% | ⏳ Pending |
| 2026-06-17 | The dramatic Alzheimer's-psilocybin claim will likely get walked back | 68% | ⏳ Pending |
| 2026-06-16 | MDMA and psilocybin stay federally illegal through 2027 | 78% | ⏳ Pending |
| 2026-06-16 | FDA will demand another full MDMA trial before approving it | 72% | ⏳ Pending |
| 2026-06-16 | No reliable biological test for predicting psychedelic therapy success by 2027 | 70% | ⏳ Pending |
| 2026-06-16 | At least one more US state will open a legal psychedelic therapy program by mid-2027 | 65% | ⏳ Pending |
| 2026-06-15 | Psychedelics stay in the most restricted drug category until at least mid-2027 | 85% | ⏳ Pending |
| 2026-06-15 | No psychedelic drug will get FDA approval or a formal review meeting before late 2026 | 80% | ⏳ Pending |
| 2026-06-15 | Congress won't hold a full floor vote on any psychedelic-focused bill before fall 2026 | 80% | ⏳ Pending |
| 2026-06-15 | The FDA will not approve MDMA as a PTSD treatment before September 2026 | 78% | ⏳ Pending |
| 2026-06-15 | No human trial of psilocybin for brain injury recovery will start before mid-2027 | 72% | ⏳ Pending |
| 2026-06-14 | US drug regulator won't approve any psychedelic medicine in 2026 | 74% | ⏳ Pending |
| 2026-06-14 | Federal law on psychedelics will not change in 2026 | 72% | ⏳ Pending |
| 2026-06-14 | Congress will not pass any psychedelic law reform in 2026 | 72% | ⏳ Pending |
| 2026-06-14 | Lab discoveries about psychedelics will race ahead of real-world clinical proof in 2026 | 72% | ⏳ Pending |
| 2026-06-14 | Brain science on psychedelics will outrun human clinical proof in 2026 | 70% | ⏳ Pending |
| 2026-06-13 | Psilocybin and MDMA stay in the most restricted drug category through 2026 | 85% | ⏳ Pending |
| 2026-06-13 | No psychedelic drug gets full FDA approval in 2026 | 76% | ⏳ Pending |
| 2026-06-13 | Congress won't broadly legalize psychedelics in 2026 — only veterans get traction | 75% | ⏳ Pending |
| 2026-06-13 | Scientists publish major new findings on exactly how psilocybin works in the brain | 74% | ⏳ Pending |
| 2026-06-13 | Veterans will be the only group to win new psychedelic access laws by mid-2027 | 70% | ⏳ Pending |
| 2026-06-12 | Congress won't change psilocybin or MDMA drug laws by 2026 | 80% | ⏳ Pending |
| 2026-06-12 | Psilocybin and dementia headlines will mislead — then get corrected | 72% | ⏳ Pending |
| 2026-06-12 | US drug cops will crack down on at least two ketamine telehealth companies | 62% | ⏳ Pending |
| 2026-06-12 | FDA will issue an official warning about at-home and compounded ketamine | 58% | ⏳ Pending |
| 2026-06-11 | Psychedelic drug reform bills won't get a real vote in 2026 | 80% | ⏳ Pending |
| 2026-06-11 | A major news outlet will expose ketamine clinic bad practices | 74% | ⏳ Pending |
| 2026-06-11 | Veterans may get ibogaine treatment funding tucked into military bill | 68% | ⏳ Pending |
| 2026-06-11 | The DEA will crack down on at least one ketamine provider | 65% | ⏳ Pending |
| 2026-06-11 | Two more VA hospitals may launch psilocybin therapy programs | 60% | ⏳ Pending |
| 2026-06-10 | Psilocybin, MDMA, and ibogaine stay fully illegal federally in 2026 | 91% | ⏳ Pending |
| 2026-06-10 | Congress will not vote on any bill to legalize or reschedule psychedelics in 2026 | 86% | ⏳ Pending |
| 2026-06-10 | A major news outlet will publish a hard-hitting investigation into ketamine clinics by early 2027 | 78% | ⏳ Pending |
| 2026-06-10 | US regulators will crack down on ketamine prescribing via telehealth by early 2027 | 74% | ⏳ Pending |
| 2026-06-10 | The DEA will publicly warn that federal drug law overrides state ibogaine programs in 2026 | 70% | ⏳ Pending |
| 2026-06-09 | Patient Choice Act won't pass Congress before January 2027 | 81% | ⏳ Pending |
| 2026-06-09 | DEA will delay any ibogaine research rule by at least 12 months | 77% | ⏳ Pending |
| 2026-06-09 | Compass Pathways stock drops below $9.50 before September 2026 | 74% | ⏳ Pending |
| 2026-06-09 | Ketamine clinics will outperform biotech index through end of 2026 | 73% | ⏳ Pending |
| 2026-06-09 | FDA warns against using single anecdotes as proof of psilocybin cures | 72% | ⏳ Pending |
| 2026-06-08 | No psychedelic drug moves out of Schedule I by end of 2026 | 80% | ⏳ Pending |
| 2026-06-08 | FDA-approved psychedelics require treatment centers and 6-hour monitoring | 76% | ⏳ Pending |
| 2026-06-08 | No published study proves psilocybin works for Alzheimer's before 2027 | 73% | ⏳ Pending |
| 2026-06-08 | Federal psychedelic research plan focuses on veterans and avoids MDMA | 72% | ⏳ Pending |
| 2026-06-08 | A large pharma company buys ketamine clinic infrastructure by September 2026 | 68% | ⏳ Pending |
| 2026-06-07 | Psilocybin and MDMA stay illegal under federal law through 2026 | 84% | ⏳ Pending |
| 2026-06-07 | Congress won't vote on psychedelic therapy bills before 2026 elections | 83% | ⏳ Pending |
| 2026-06-07 | FDA rejects MDMA-assisted therapy application, requests more data | 81% | ⏳ Pending |
| 2026-06-07 | DEA raids at least three ketamine clinics across different states | 72% | ⏳ Pending |
| 2026-06-07 | Two more states legalize psilocybin therapy by end of 2026 | 61% | ⏳ Pending |
| 2026-06-06 | Major US medical groups won't restrict ketamine for psychiatry based on rat studies by Oct 2026 | 78% | ⏳ Pending |
| 2026-06-06 | DEA will formally oppose psilocybin rescheduling before mid-2027, keeping it illegal | 75% | ⏳ Pending |
| 2026-06-06 | FDA will ask Mindmed for more MDMA-PTSD safety data, not approve or reject outright | 74% | ⏳ Pending |
| 2026-06-06 | Mindmed stock will beat ATAI and Compass on returns through September 2026 | 72% | ⏳ Pending |
| 2026-06-06 | ATAI and Compass will underperform the broader biotech sector through September 2026 | 71% | ⏳ Pending |
| 2026-06-05 | No psychedelic drug gets FDA approval in 2026 | 93% | ⏳ Pending |
| 2026-06-05 | Psilocybin won't get FDA approval before September 2028 | 81% | ⏳ Pending |
| 2026-06-05 | DEA will formally oppose psilocybin rescheduling by mid-2027 | 78% | ⏳ Pending |
| 2026-06-05 | Announced veteran psychedelic program enrolls zero patients by end-2026 | 74% | ⏳ Pending |
| 2026-06-05 | Major media outlets expose gap between veteran psychedelic promises and real access by end-2026 | 62% | ⏳ Pending |
| 2026-06-04 | Ketamine becomes the dominant billable psychedelic treatment by 2027 | 82% | ⏳ Pending |
| 2026-06-04 | DEA formally opposes ibogaine legal exemption in Congress | 74% | ⏳ Pending |
| 2026-06-04 | Scientists publish psilocybin brain-healing findings in top journals | 73% | ⏳ Pending |
| 2026-06-04 | FDA rejects MDMA therapy approval again in late 2026 | 72% | ⏳ Pending |
| 2026-06-04 | U.S. medical centers launch ketamine trials for suicidal youth | 71% | ⏳ Pending |
| 2026-06-03 | Mindmed stock will drop 8% within two weeks without major news | 80% | ⏳ Pending |
| 2026-06-03 | Federal psilocybin rescheduling will stall through 2027 | 78% | ⏳ Pending |
| 2026-06-03 | DEA will prosecute two ketamine clinics for illegal prescribing by 2026 | 72% | ⏳ Pending |
| 2026-06-03 | Ibogaine veteran treatment will enter defense bill by end of 2026 | 65% | ⏳ Pending |
| 2026-06-03 | Three medical schools will test ketamine plus add-on drugs by 2027 | 62% | ⏳ Pending |
| 2026-06-02 | No psychedelic drug will be rescheduled before March 2027 | 85% | ⏳ Pending |
| 2026-06-02 | Trump psychedelic fast-track order will produce zero regulatory changes by October 2026 | 80% | ⏳ Pending |
| 2026-06-02 | FDA rejects MDMA-PTSD approval, citing safety concerns by end of 2026 | 78% | ⏳ Pending |
| 2026-06-02 | Lykos Therapeutics shuts down, gets bought, or abandons MDMA program by 2026 | 74% | ⏳ Pending |
| 2026-06-02 | Three more states legalize psychedelics for veterans before 2027 | 72% | ⏳ Pending |
| 2026-06-01 | Psilocybin won't be rescheduled federally before 2028 | 82% | ⏳ Pending |
| 2026-06-01 | Three more states legalize psilocybin therapy or decriminalize before 2026 ends | 77% | ⏳ Pending |
| 2026-06-01 | Compass stock drops back to $12.80–$13.40 within one week | 74% | ⏳ Pending |
| 2026-06-01 | DEA will publicly prosecute unlicensed retreat operators before September 2026 | 73% | ⏳ Pending |
| 2026-06-01 | U.S. lawmakers will frame psychedelic reform around veterans | 72% | ⏳ Pending |
| 2026-05-31 | DEA won't move on psilocybin or MDMA without FDA approval by end of 2026 | 88% | ⏳ Pending |
| 2026-05-31 | Congress won't vote on a psychedelic scheduling reform bill by end of 2026 | 85% | ⏳ Pending |
| 2026-05-31 | Three or more US states will propose veteran psychedelic therapy bills by end of 2026 | 81% | ⏳ Pending |
| 2026-05-31 | Compass Pathways stock will drop 5% within two weeks of May 31, 2026 | 79% | ⏳ Pending |
| 2026-05-31 | Major news outlet will expose ketamine clinic safety or financial problems by fall 2026 | 72% | ⏳ Pending |
| 2026-05-30 | Psilocybin won't get rescheduled federally before January 2028 | 82% | ⏳ Pending |
| 2026-05-30 | MDMA won't get rescheduled federally before January 2028 | 79% | ⏳ Pending |
| 2026-05-30 | Compass Pathways stock will drop sharply after its recent spike | 77% | ⏳ Pending |
| 2026-05-30 | DEA will block Congress from bypassing psilocybin scheduling rules | 72% | ⏳ Pending |
| 2026-05-30 | FDA will approve psilocybin research for broader depression, not just severe cases | 68% | ⏳ Pending |
| 2026-05-29 | No new state legislatures will legalize psychedelics by end of 2026 | 85% | ⏳ Pending |
| 2026-05-29 | Congress won't vote on federal psychedelic bills before November 2026 | 82% | ⏳ Pending |
| 2026-05-29 | DEA won't reschedule psilocybin before 2029 due to bureaucratic rules | 81% | ⏳ Pending |
| 2026-05-29 | Medicare won't pay for psilocybin therapy by end of 2028 | 78% | ⏳ Pending |
| 2026-05-29 | Compass Pathways stock will drop below $12 within 15 trading days | 76% | ✗ Did not happen |
| 2026-05-28 | MDMA won't get FDA approval in 2026, gets rejection letter instead | 73% | ⏳ Pending |
| 2026-05-28 | FDA will warn doctors about ketamine and suicidality risk before October 2026 | 72% | ⏳ Pending |
| 2026-05-28 | At least three states introduce ibogaine access bills for veterans by end of 2026 | 68% | ⏳ Pending |
| 2026-05-28 | MDMA PTSD study results published in major journal by September 2026 | 62% | ⏳ Pending |
| 2026-05-28 | Major news outlet investigates deaths at unregulated psychedelic retreats by September 2026 | 62% | ⏳ Pending |
| 2026-05-27 | MDMA therapy won't get FDA approval in 2026; company must start over | 82% | ⏳ Pending |
| 2026-05-27 | DEA will shut down at least two unregulated psychedelic retreat operators before September 2026 | 72% | ⏳ Pending |
| 2026-05-27 | At least one struggling psychedelic company will explore mergers before end of Q3 2026 | 71% | ⏳ Pending |
| 2026-05-27 | Congress will hold hearings on unregulated retreat safety after a publicized death | 68% | ⏳ Pending |
| 2026-05-27 | FDA will update ketamine therapy safety warnings or instructions for doctors by February 2027 | 64% | ⏳ Pending |
| 2026-05-26 | Veteran suicide data will feature in three major congressional budget speeches, linking ibogaine access to military ment | 81% | ⏳ Pending |
| 2026-05-26 | FDA will delay MDMA drug approval decision until mid-2027, requesting more cardiovascular safety data. | 79% | ⏳ Pending |
| 2026-05-26 | MDMA approval decision will slip to mid-2027 at earliest; 2026 approval unlikely. | 77% | ⏳ Pending |
| 2026-05-26 | Major news outlet will expose ketamine clinic safety failures before end of 2026. | 77% | ⏳ Pending |
| 2026-05-26 | DEA and FDA will pressure ketamine clinics with enforcement actions before early 2027. | 76% | ⏳ Pending |
| 2026-05-25 | FDA rejects MDMA therapy, demands another trial on blinding | 74% | ⏳ Pending |
| 2026-05-25 | Stanford's ibogaine study releases veteran outcomes by mid-2026 | 72% | ⏳ Pending |
| 2026-05-25 | A veteran testifies to Congress about their ibogaine treatment | 68% | ⏳ Pending |
| 2026-05-25 | Study published: MDMA blinding doesn't work in most trials | 65% | ⏳ Pending |
| 2026-05-25 | Major news outlet exposes Republican ties to psychedelic companies | 62% | ⏳ Pending |
| 2026-05-24 | Psilocybin stays illegal at federal level through 2028 | 85% | ⏳ Pending |
| 2026-05-24 | Only Oregon and Colorado approve legal psilocybin therapy by 2028 | 72% | ⏳ Pending |
| 2026-05-24 | Three major science journals publish psychedelic brain research in 2026 | 65% | ⏳ Pending |
| 2026-05-24 | A Phase 3 psychedelic trial hits its main goal by late 2026 | 62% | ⏳ Pending |
| 2026-05-24 | Congress funds psychedelic research for veterans by late 2026 | 58% | ⏳ Pending |
| 2026-05-23 | News outlet will badly distort a psilocybin study finding by August 2026 | 78% | ⏳ Pending |
| 2026-05-23 | DEA will formally oppose letting military veterans access ibogaine | 76% | ⏳ Pending |
| 2026-05-23 | FDA will keep requiring heart monitoring for ibogaine trials through mid-2027 | 74% | ⏳ Pending |
| 2026-05-23 | Scientists will cite ibogaine brain plasticity finding in five new studies by May 2027 | 62% | ⏳ Pending |
| 2026-05-23 | Major news outlet will confuse psilocybin addiction research with recreational microdosing by July 2026 | 48% | ⏳ Pending |
| 2026-05-22 | FDA requires heart monitoring for ibogaine clinical trials by end of 2026 | 72% | ⏳ Pending |
| 2026-05-22 | Most new state psychedelic bills in 2026 target veterans with ibogaine | 68% | ⏳ Pending |
| 2026-05-22 | DEA will publicly charge at least two unlicensed psychedelic clinics by end of 2026 | 65% | ⏳ Pending |
| 2026-05-22 | No new psychedelic will get FDA fast-track approval status in 2026 | 61% | ⏳ Pending |
| 2026-05-22 | Two states will pass ibogaine access laws for veterans before July 2027 | 52% | ⏳ Pending |
| 2026-05-21 | FDA will require heart monitoring for ibogaine veteran programs by early 2027 | 72% | ⏳ Pending |
| 2026-05-21 | US ibogaine retreats marketing to veterans will grow 40% by mid-2027 | 63% | ⏳ Pending |
| 2026-05-21 | A death at an unregulated ibogaine retreat will trigger congressional investigation | 61% | ✓ Came true |
| 2026-05-21 | A major pharmaceutical company will acquire a psilocybin psychedelic firm by early 2027 | 52% | ⏳ Pending |
| 2026-05-21 | NIH will fund at least three ibogaine plasticity research grants within 18 months | 48% | ⏳ Pending |
| 2026-05-20 | Psilocybin stays illegal until at least end of 2027 | 88% | ⏳ Pending |
| 2026-05-20 | Major news will hype psilocybin addiction cure, then quietly correct | 78% | ✗ Did not happen |
| 2026-05-20 | Psilocybin NDA filed for depression treatment by late 2027 | 62% | ⏳ Pending |
| 2026-05-20 | Ibogaine brain plasticity finding sparks three NIH grants | 38% | ⏳ Pending |
| 2026-05-19 | Ibogaine stays illegal through 2029 because of heart risks, despite veteran pressure | 71% | ⏳ Pending |
| 2026-05-19 | Compass Pathways stock won't bounce back above $12.50 by August 2026 | 67% | ⏳ Pending |
| 2026-05-19 | Psilocybin-cocaine study gets mangled in 72 hours, then correction itself becomes a credibility scandal | 62% | ✗ Did not happen |
| 2026-05-18 | FDA will require heart screening before approving ibogaine studies | 82% | ⏳ Pending |
| 2026-05-18 | Researchers will study why psilocybin blocks cocaine relapse so effectively | 79% | ⏳ Pending |
| 2026-05-18 | Senate will hold ibogaine hearings with Stanford researchers by September 2026 | 78% | ⏳ Pending |
| 2026-05-18 | Major news outlet will expose ibogaine cardiac deaths in veteran programs | 76% | ⏳ Pending |
| 2026-05-18 | Compass stock outperforms MindMed on psilocybin depression data | 74% | ⏳ Pending |
| 2026-05-18 | Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT | 71% | ⏳ Pending |
| 2026-05-18 | California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psy | 70% | ⏳ Pending |
| 2026-05-17 | No psychedelic drug becomes legal medicine in US before 2028 | 82% | ⏳ Pending |
| 2026-05-17 | Psychedelic company stocks stay flat or lose money through 2026 | 68% | ⏳ Pending |
| 2026-05-17 | NIH funds 5+ ibogaine brain studies within 2 years, including non-hallucinogenic versions | 55% | ⏳ Pending |
| 2026-05-17 | FDA requires heart screening for ibogaine before therapeutic programs start | 52% | ⏳ Pending |
| 2026-05-17 | Anti-drug politicians cite psilocybin-cocaine study in congressional testimony within 12 months | 28% | ⏳ Pending |
| 2026-05-17 | Federal ibogaine cardiac safety rules delay therapeutic access by 18+ months | 18% | ⏳ Pending |
| 2026-05-16 | FDA demands heart screening before ibogaine trials expand | 62% | ⏳ Pending |
| 2026-05-16 | Three non-psychedelic ibogaine drugs will start lab testing | 61% | ⏳ Pending |
| 2026-05-16 | Congress forms psychedelic study group before 2027, no laws until 2028 | 58% | ⏳ Pending |
| 2026-05-16 | Two companies will ask FDA for fast-track psilocybin approval | 38% | ⏳ Pending |
| 2026-05-15 | Ibogaine stays illegal Schedule I drug through 2028 | 72% | ⏳ Pending |
| 2026-05-15 | Psilocybin-cocaine study sparks 10+ papers on brain mechanisms within 2 years | 62% | ⏳ Pending |
| 2026-05-15 | FDA publishes cardiac monitoring rules for ibogaine trials by end of 2026 | 41% | ⏳ Pending |
| 2026-05-15 | US government funds $50M+ ibogaine research and plasticity studies by late 2027 | 38% | ⏳ Pending |
| 2026-05-15 | Federal ibogaine cardiac monitoring rules written into law by August 2026 | 7% | ⏳ Pending |
| 2026-05-14 | States lead U.S. psychedelic policy ahead of federal action through 2027 | 72% | ⏳ Pending |
| 2026-05-14 | Ibogaine plasticity research spawns 5+ studies and 2 consortia by 2027 | 62% | ⏳ Pending |
| 2026-05-14 | Federal regulators or Congress formally address ibogaine cardiac safety by 2026 | 52% | ⏳ Pending |
| 2026-05-14 | FDA issues formal cardiac safety warning on ibogaine by late 2026 | 44% | ⏳ Pending |
| 2026-05-13 | Ibogaine won't get federal approval or rescheduling by early 2028 | 88% | ⏳ Pending |
| 2026-05-13 | No federal psychedelic law reform will reach a floor vote by end of 2028 | 78% | ⏳ Pending |
| 2026-05-13 | DEA will formally reject any ibogaine rescheduling request by 2028 | 68% | ⏳ Pending |
| 2026-05-13 | FDA will issue a cardiac safety warning on ibogaine by end of 2026 | 42% | ⏳ Pending |
| 2026-05-13 | A safer ibogaine alternative will raise over $30M by spring 2027 | 38% | ⏳ Pending |
| 2026-05-12 | Media will hype psilocybin cocaine study as 'cure,' then print corrections | 72% | ⏳ Pending |
| 2026-05-12 | Congress holds public hearing on FDA's ibogaine policy and access | 55% | ⏳ Pending |
| 2026-05-12 | Research team launches new psilocybin addiction study with clear science | 52% | ⏳ Pending |
| 2026-05-12 | FDA warns the public about ibogaine heart rhythm dangers | 38% | ⏳ Pending |
| 2026-05-12 | FDA cardiac warning on ibogaine causes split in synthetic drug approval | 28% | ⏳ Pending |
| 2026-05-11 | Psilocybin research will spawn three competing theories about extinction without relapse | 72% | ⏳ Pending |
| 2026-05-11 | US states will pass four new psychedelic therapy laws while Congress stays frozen | 70% | ⏳ Pending |
| 2026-05-11 | Veterans will access psychedelic retreats outside the US by 5,000 by late 2026 | 55% | ⏳ Pending |
| 2026-05-11 | FDA will formally warn about ibogaine heart rhythm dangers by February 2027 | 52% | ⏳ Pending |
| 2026-05-11 | FDA or DEA will restrict ibogaine access before it expands in the US | 28% | ⏳ Pending |
| 2026-05-10 | States will open legal psilocybin therapy programs before federal law changes | 78% | ⏳ Pending |
| 2026-05-10 | FDA will demand repeat studies of psilocybin for cocaine addiction, approval by 2029 | 76% | ⏳ Pending |
| 2026-05-10 | Any approved ibogaine treatment will require mandatory heart monitoring, approval by 2028 | 74% | ⏳ Pending |
| 2026-05-10 | FDA issues cardiac safety warning on ibogaine, delaying approval 12–18 months | 72% | ⏳ Pending |
| 2026-05-10 | California passes legal psilocybin therapy law before end of 2026 | 52% | ⏳ Pending |
| 2026-05-10 | Congressional hearing triggered by veteran death in unregulated ibogaine treatment | 48% | ⏳ Pending |
| 2026-05-09 | Ibogaine development stalls due to cardiac safety concerns and regulatory blocks | 71% | ⏳ Pending |
| 2026-05-09 | FDA issues formal safety alert on ibogaine heart monitoring by end of 2026 | 62% | ⏳ Pending |
| 2026-05-09 | Two major companies file new psilocybin trials for cocaine addiction by 2026 | 52% | ⏳ Pending |
| 2026-05-09 | DEA blocks ibogaine rescheduling using new cardiac safety evidence by 2026 | 41% | ⏳ Pending |
| 2026-05-09 | Two psilocybin cocaine addiction trials launch within three months | 18% | ⏳ Pending |
| 2026-05-08 | No classical psychedelic will be rescheduled federally before 2028 | 80% | ⏳ Pending |
| 2026-05-08 | DEA delays psilocybin access by 18+ months after any FDA approval | 78% | ⏳ Pending |
| 2026-05-08 | FDA mandates heart monitoring for ibogaine, delaying veteran therapy access | 75% | ⏳ Pending |
| 2026-05-08 | A serious retreat injury will trigger state-level safety crackdowns by 2026 | 62% | ⏳ Pending |
| 2026-05-08 | Ibogaine splits into two paths: natural (restricted) and synthetic (faster approval) | 55% | ⏳ Pending |
| 2026-05-07 | Psilocybin rescheduling won't get a Congressional vote by January 2027 | 87% | ⏳ Pending |
| 2026-05-07 | No psychedelic rescheduling at federal level before 2028 | 85% | ⏳ Pending |
| 2026-05-07 | Ibogaine heart safety will block FDA progress through mid-2027 | 78% | ⏳ Pending |
| 2026-05-07 | FDA will warn about ibogaine heart rhythm dangers by end of 2026 | 72% | ⏳ Pending |
| 2026-05-07 | FDA won't publish SSRI-psychedelic interaction guidance by November 2027 | 70% | ⏳ Pending |
| 2026-05-06 | Medical schools will teach psychedelic therapy as standard psychiatry by 2028 | 94% | ⏳ Pending |
| 2026-05-06 | Microdosing becomes the fastest-growing psychedelic research area in 2026 | 91% | ⏳ Pending |
| 2026-05-06 | Both parties in Congress will formally acknowledge psychedelic therapy as legitimate medicine by end of 2026 | 88% | ⏳ Pending |
| 2026-05-06 | First psychedelic drug approved by FDA by end of 2027 | 87% | ⏳ Pending |
| 2026-05-06 | Psychedelic stocks will be higher in October than they were before Trump's order | 83% | ⏳ Pending |
| 2026-05-06 | Legal psychedelic therapy access program opens in the US before 2027 | 79% | ⏳ Pending |
| 2026-05-06 | Psilocybin shown to work for something beyond depression or PTSD | 76% | ⏳ Pending |
| 2026-05-06 | DEA begins formal process to move psilocybin out of Schedule I | 71% | ⏳ Pending |
| 2026-05-06 | A major drug company will buy or partner with a psychedelic biotech this year | 62% | ⏳ Pending |
| 2026-05-05 | Congress won't pass a standalone psychedelic bill before mid-2026 | 90% | ⏳ Pending |
| 2026-05-05 | Two more states will propose veteran psychedelic therapy access laws in 2026 | 78% | ⏳ Pending |
| 2026-05-05 | DEA will formally oppose any law letting veterans skip ibogaine review | 72% | ⏳ Pending |
| 2026-05-05 | FDA will require heart screening before testing ibogaine in humans | 62% | ⏳ Pending |
| 2026-05-05 | Ibogaine companies will publicly switch to safer chemical alternatives | 58% | ⏳ Pending |
| 2026-05-04 | FDA publishes heart-safety rules for ibogaine trials | 52% | ⏳ Pending |
| 2026-05-04 | Congressional hearing or federal probe triggered by ketamine clinic harm | 38% | ⏳ Pending |
| 2026-05-04 | FDA heart-safety guidance delays at least one ibogaine IND approval | 31% | ⏳ Pending |
| 2026-05-04 | Trial protocols cite SSRI drug interaction research in washout rules | 28% | ⏳ Pending |
| 2026-05-04 | SSRI washout rules mandated across multiple trials by mid-2026 | 14% | ⏳ Pending |
| 2026-05-03 | Any federal ibogaine law will require cardiac screening if it passes | 71% | ⏳ Pending |
| 2026-05-03 | Mind Medicine stock stays flat or down through September 2026 | 68% | ⏳ Pending |
| 2026-05-03 | Psychedelic biotech sector flat or down by early June 2026 | 61% | ⏳ Pending |
| 2026-05-03 | FDA issues formal cardiac screening rules for ibogaine trials | 52% | ⏳ Pending |
| 2026-05-03 | Ibogaine research shifts focus to brain chemistry pathway by 2028 | 48% | ⏳ Pending |
| 2026-05-03 | Cardiac screening becomes mandatory in one federal ibogaine bill or guidance | 44% | ⏳ Pending |
| 2026-05-02 | No psychedelic drug will be approved or rescheduled by end of 2026 | 82% | ⏳ Pending |
| 2026-05-02 | Psychedelic biotech stocks won't recover to 2024 peaks by September 2026 | 80% | ⏳ Pending |
| 2026-05-02 | FDA will mandate cardiac monitoring for ibogaine drug trials by January 2027 | 79% | ⏳ Pending |
| 2026-05-02 | Psychedelic biotech stocks will stay depressed through September 2026 | 78% | ⏳ Pending |
| 2026-05-02 | Ibogaine heart risk will force FDA to delay trials into 2027 | 72% | ⏳ Pending |
| 2026-05-01 | FDA requires heart screening tests for ibogaine drug trials | 62% | ⏳ Pending |
| 2026-05-01 | Two major psilocybin trials will require patients to stop antidepressants | 52% | ⏳ Pending |
| 2026-05-01 | Safer ibogaine versions will be worth much more than original | 48% | ⏳ Pending |
| 2026-05-01 | FDA may halt a psilocybin trial over treatment endpoint mismatch | 38% | ⏳ Pending |
| 2026-05-01 | Psilocybin trials will require antidepressant washout by July 2026 | 28% | ⏳ Pending |
| 2026-04-30 | DEA keeps psilocybin and MDMA illegal through October 2026 | 88% | ⏳ Pending |
| 2026-04-30 | MAPS or Compass publishes psilocybin trial safety or enrollment update | 80% | ⏳ Pending |
| 2026-04-30 | Congress introduces a bipartisan bill supporting psychedelic research | 62% | ⏳ Pending |
| 2026-04-30 | Compass or MAPS announces Phase 3 results or FDA pre-approval meeting | 55% | ⏳ Pending |
| 2026-04-30 | Congress introduces bill protecting Indigenous plant medicine and sovereignty rights | 42% | ⏳ Pending |
| 2026-04-30 | One US state passes a psychedelic therapy or decriminalization law | 38% | ⏳ Pending |
| 2026-04-30 | US insurer or Medicare announces psychedelic therapy reimbursement guidance | 8% | ⏳ Pending |
| 2026-04-29 | No ibogaine product gets FDA approval before 2030 | 84% | ⏳ Pending |
| 2026-04-29 | DEA keeps all psychedelics in Schedule I without rescheduling by 2028 | 77% | ⏳ Pending |
| 2026-04-29 | No federal ibogaine approval pathway established by 2029 | 76% | ⏳ Pending |
| 2026-04-29 | Three more states pass ibogaine access laws for veterans by end of 2027 | 62% | ⏳ Pending |
| 2026-04-29 | Five independent studies replicate fluoxetine-psychedelic interaction by April 2028 | 58% | ⏳ Pending |
| 2026-04-29 | Fluoxetine-psychedelic screening becomes required in federal psychedelic trials by April 2028 | 52% | ⏳ Pending |
| 2026-04-29 | FDA issues protocol guidance on fluoxetine-psychedelic data by Q2 2027 | 45% | ⏳ Pending |
| 2026-04-28 | No psychedelic substance is rescheduled from Schedule I to Schedule II or III in the United States before January 1, 202 | 77% | ⏳ Pending |
| 2026-04-28 | Ibogaine's cardiac safety profile causes at least one major clinical trial sponsor to publicly pause or redesign an ibog | 70% | ⏳ Pending |
| 2026-04-28 | Oxa-noribogaine enters a human Phase 1 clinical trial before October 31, 2027 | 62% | ⏳ Pending |
| 2026-04-28 | CMPS (Compass Pathways) closes below $7.00 on at least one trading day before June 30, 2026 | 45% | ⏳ Pending |
| 2026-04-28 | FDA issues a formal guidance document specifically addressing psychedelic-SSRI pharmacodynamic interactions and washout | 38% | ⏳ Pending |
| 2026-04-27 | Ibogaine will become the central contested exhibit in the 2026-2027 psychedelic safety culture war, simultaneously weapo | 78% | ⏳ Pending |
| 2026-04-27 | Ibogaine cardiac safety concerns will materially slow or condition U.S. regulatory pathways, requiring mandatory cardiac | 76% | ⏳ Pending |
| 2026-04-27 | Psilocybin will be the first classic psychedelic to receive FDA NDA acceptance for review for treatment-resistant MDD, w | 74% | ⏳ Pending |
| 2026-04-27 | Fluoxetine-psychedelic interaction data will be incorporated into FDA guidance requiring standardized SSRI washout crite | 72% | ⏳ Pending |